Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease

PURPOSE: The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI adverse events in patients with underlying IBD who received immune checkpoint inhibitors. PATIENTS AND METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Sbeih, Hamzah, Faleck, David M., Ricciuti, Biagio, Mendelsohn, Robin B., Naqash, Abdul R., Cohen, Justine V., Sellers, Maclean C., Balaji, Aanika, Ben-Betzalel, Guy, Hajir, Ibraheim, Zhang, Jiajia, Awad, Mark M., Leonardi, Giulia C., Johnson, Douglas B., Pinato, David J., Owen, Dwight H., Weiss, Sarah A., Lamberti, Giuseppe, Lythgoe, Mark P., Manuzzi, Lisa, Arnold, Christina, Qiao, Wei, Naidoo, Jarushka, Markel, Gal, Powell, Nick, Yeung, Sai-Ching J., Sharon, Elad, Dougan, Michael, Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030892/
https://www.ncbi.nlm.nih.gov/pubmed/31800340
http://dx.doi.org/10.1200/JCO.19.01674

Ejemplares similares

Ejemplares similares